FDA to study reusing medical devices — could save hospitals millions

What it does

This bill directs the FDA to study whether single-use medical devices (like catheters or surgical instruments designed to be thrown away after one use) can be safely reprocessed and reused. The study will examine existing FDA rules, the role of third-party reprocessing companies versus hospitals doing it in-house, operational and financial feasibility, liability issues, and environmental benefits. The FDA must report findings within one year, identifying which devices could be reprocessed and recommending programs to expand reprocessing.

Why we flagged it

The bill's sole operative mechanism is a directed study by the FDA on the safety and feasibility of reprocessing single-use medical devices. It is a fact-finding and reporting mandate, not a regulatory change or appropriation.

What the text implies

• Study findings could inform future FDA rulemaking that expands reprocessing pathways, potentially reducing device manufacturer revenue if reuse becomes standard practice for certain devices.
• Liability and accountability findings may influence hospital and third-party reprocessor behavior, potentially shifting risk allocation in ways that affect insurance and litigation patterns.
• Environmental and cost-savings data could create political pressure for regulatory or reimbursement changes favoring reprocessing, indirectly affecting device manufacturers' market share.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

The bill creates a fact-finding mechanism on a practice that could reduce healthcare costs for patients and hospitals, lower medical waste, and improve environmental outcomes — all without imposing new restrictions on patient safety or creating liability shields. The study is explicitly anchored to patient safety and infection prevention as primary criteria, and consultation includes infection-prevention and clinical organizations.

Who stands to gain

• hospitals (potential cost savings from device reuse)
• third-party medical device reprocessors (potential market expansion)
• healthcare systems (waste reduction and operational efficiency)

Named in the bill

FDA (Food and Drug Administration), HHS (Department of Health and Human Services), CDC (Centers for Disease Control and Prevention), CMS (Centers for Medicare & Medicaid Services), third-party reprocessors, hospitals, medical device manufacturers

Where it stands

• Aug 13, 2026 — Introduced · Congress.gov: “Introduced in House”
• Aug 13, 2026 — Referred to House Committee on Energy and Commerce · Congress.gov: “Referred to the House Committee on Energy and Commerce”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.